X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 28.3 14.2 199.3% View Chart
P/BV x 6.5 3.8 172.2% View Chart
Dividend Yield % 0.7 0.3 226.6%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs792993 79.7%   
Low Rs443729 60.7%   
Sales per share (Unadj.) Rs167.0325.5 51.3%  
Earnings per share (Unadj.) Rs38.239.3 97.1%  
Cash flow per share (Unadj.) Rs42.048.7 86.3%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.2 279.0%  
Book value per share (Unadj.) Rs84.9159.2 53.3%  
Shares outstanding (eoy) m188.52282.17 66.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.72.6 139.7%   
Avg P/E ratio x16.221.9 73.8%  
P/CF ratio (eoy) x14.717.7 83.1%  
Price / Book Value ratio x7.35.4 134.4%  
Dividend payout %10.55.1 205.9%   
Avg Mkt Cap Rs m116,383242,991 47.9%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m4,21416,408 25.7%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m31,48791,857 34.3%  
Other income Rs m55374 14.7%   
Total revenues Rs m31,54292,230 34.2%   
Gross profit Rs m10,06020,367 49.4%  
Depreciation Rs m7222,644 27.3%   
Interest Rs m372,373 1.6%   
Profit before tax Rs m9,35615,724 59.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,1603,827 56.4%   
Profit after tax Rs m7,19411,088 64.9%  
Gross profit margin %31.922.2 144.1%  
Effective tax rate %23.124.3 94.9%   
Net profit margin %22.812.1 189.3%  
BALANCE SHEET DATA
Current assets Rs m15,06668,746 21.9%   
Current liabilities Rs m7,67427,027 28.4%   
Net working cap to sales %23.545.4 51.7%  
Current ratio x2.02.5 77.2%  
Inventory Days Days6785 78.8%  
Debtors Days Days4196 42.5%  
Net fixed assets Rs m8,23724,132 34.1%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m15,41644,643 34.5%   
Net worth Rs m16,00544,925 35.6%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m24,594117,639 20.9%  
Interest coverage x255.27.6 3,347.1%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.30.8 164.0%   
Return on assets %29.411.4 257.0%  
Return on equity %44.924.7 182.1%  
Return on capital %58.719.1 306.5%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81156,152 31.7%   
Fx outflow Rs m5,3188,084 65.8%   
Net fx Rs m12,49348,068 26.0%   
CASH FLOW
From Operations Rs m9,3046,574 141.5%  
From Investments Rs m-3,105-7,124 43.6%  
From Financial Activity Rs m-1,9595,432 -36.1%  
Net Cashflow Rs m4,2401,992 212.8%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS